Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of “Buy” from Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have been given a consensus rating of “Buy” by the six analysts that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $7.67.

A number of research firms have recently commented on PSNL. HC Wainwright raised their target price on Personalis from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, May 7th. Craig Hallum assumed coverage on shares of Personalis in a research note on Monday, March 17th. They set a “buy” rating and a $8.00 price objective on the stock. Guggenheim began coverage on Personalis in a research report on Thursday, May 15th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th.

Personalis Stock Performance

Shares of PSNL stock opened at $4.72 on Thursday. Personalis has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The firm has a market cap of $416.89 million, a P/E ratio of -2.81 and a beta of 1.83. The business’s 50 day moving average price is $3.84 and its 200-day moving average price is $4.46.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $20.61 million for the quarter, compared to analysts’ expectations of $17.41 million. As a group, equities analysts predict that Personalis will post -1.4 EPS for the current year.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Personalis in the 4th quarter worth $28,000. JPMorgan Chase & Co. increased its holdings in Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after buying an additional 5,654 shares in the last quarter. Focus Partners Wealth purchased a new position in Personalis in the 1st quarter worth about $47,000. Olympiad Research LP bought a new position in Personalis during the 4th quarter valued at about $59,000. Finally, Alpine Global Management LLC purchased a new stake in shares of Personalis during the 4th quarter valued at about $60,000. 61.91% of the stock is owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.